PDCD1 and neoplasm: While some argue that increased PD-L1 expression alone indicates greater response to immune checkpoint inhibitor therapy, it is the increased interaction of PD-1 with PD-L1 on tumor cells that correlates with increased susceptibility to immune checkpoint inhibitor therapy in NSCLC [35,36].